IL6 and neoplasm: In agreement with the present pathway analyses, we previously reported that the higher 50 mg/kg dose of AR‐42 reduced serum IL‐6 levels, as well as gastrocnemius IL‐6 receptor mRNA abundance in tumor‐bearing mice, suggesting AR‐42's efficacy may be related to its suppression of systemic IL‐6 activation, which is thought to drive muscle wasting in the C‐26 model (Tseng et al, 2015a).